EUVIMEDEUVIMED entdecken
VergleichsstudieRandomisierte kontrollierte StudieOpen Access

Dolutegravir- Versus Efavirenz-Based Treatment in Pregnancy: Impact on Red Blood Cell Folate Concentrations in Pregnant Women and Their Infants

Denise L Jacobson iD, Krista S Crider, Patricia DeMarrais, Sean Brummel, Mindy Zhang, Christine M Pfeiffer, Cynthia A Moore, Katie McCarthy, Benjamin Johnston, Terence Mohammed, Tichaona Vhembo, Enid Kabugho und 10 weitere

The Journal of Infectious Diseases · 2024

DOI: 10.1093/infdis/jiae308 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Denise L Jacobson und 21 weiteren Autor:innen. Beteiligte Einrichtung: Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. Hauptthemen laut MEDLINE: Anti-HIV Agents, Benzoxazines, Erythrocytes, Folic Acid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 2010/VESTED study, pregnant women were randomized to initiate dolutegravir (DTG) + emtricitabine (FTC)/tenofovir alafenamide (TAF), DTG + FTC/tenofovir disoproxil fumarate (TDF), or efavirenz (EFV)/FTC/TDF.

Methods

We assessed red blood cell (RBC) folate concentrations at maternal study entry and delivery, and infant birth. RBC folate outcomes were (1) maternal change entry to delivery (trajectory), (2) infant, and (3) ratio of infant-to-maternal delivery. Generalized estimating equation models for each log(folate) outcome were fit to estimate adjusted geometric mean ratio (Adj-GMR)/GMR trajectories (Adj-GMRTs) of each arm comparison in 340 mothers and 310 infants.

Results

Overall, 90% of mothers received folic acid supplements and 78% lived in Africa. At entry, median maternal age was 25 years, gestational age was 22 weeks, CD4 count was 482 cells/μL, and log10 HIV RNA was 3 copies/mL. Entry RBC folate was similar across arms. Adj-GMRT of maternal folate was 3% higher in the DTG + FTC/TAF versus EFV/FTC/TDF arm (1.03 [95% confidence interval {CI}, 1.00–1.06]). The DTG + FTC/TAF arm had an 8% lower infant-maternal folate ratio (0.92 [95% CI, .78–1.09]) versus EFV/FTC/TDF.

Conclusions

Results are consistent, with no clinically meaningful differences between arms for all RBC folate outcomes, and they suggest that cellular uptake of folate and folate transport to the infant do not differ in pregnant women starting DTG- versus EFV-based antiretroviral therapy. Clinical Trials Registration NCT03048422.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsBenzoxazinesErythrocytesFolic AcidHIV InfectionsPiperazinesPregnancy Complications, InfectiousAdolescentAdultFemaleHumansInfantInfant, NewbornPregnancyYoung AdultAlkynesCyclopropanesEmtricitabineHeterocyclic Compounds, 3-RingOxazinesPyridonesTenofovirDolutegravir

Stichwörter der Autor:innen

dolutegravirefavirenzinfantpregnancyred blood cell folate concentrations

Substanzen

AlkynesAnti-HIV AgentsBenzoxazinesCyclopropanesEmtricitabineFolic AcidHeterocyclic Compounds, 3-RingOxazinesPiperazinesPyridones

Autor:innen und Institutionen

  • Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
  • National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Goldbelt Professional Services, LLC, Chesapeake, Virginia.
  • FHI 360, Durham, North Carolina.
  • Frontier Science Foundation, Amherst, New York.

ORCID-Profile: Denise L Jacobson

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • NIH HHS
  • Intramural CDC HHS
  • NICHD NIH HHS
  • NIMH NIH HHS
  • Eunice Kennedy Shriver
  • National Institute of Child Health and Human Development

Zitieren

APA

Jacobson, D. L., Crider, K. S., DeMarrais, P., Brummel, S., Zhang, M., Pfeiffer, C. M., Moore, C. A., McCarthy, K., Johnston, B., Mohammed, T., Vhembo, T., Kabugho, E., Muzorah, G. A., Cassim, H., Fairlie, L., Machado, E. S., Ngocho, J. S., Shapiro, R. L., Serghides, L., …, & Lockman, S. (2024). Dolutegravir- Versus Efavirenz-Based Treatment in Pregnancy: Impact on Red Blood Cell Folate Concentrations in Pregnant Women and Their Infants. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae308

Vancouver

Jacobson DL, Crider KS, DeMarrais P, Brummel S, Zhang M, Pfeiffer CM, et al. Dolutegravir- Versus Efavirenz-Based Treatment in Pregnancy: Impact on Red Blood Cell Folate Concentrations in Pregnant Women and Their Infants. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae308

BibTeX
@article{Jacobson2024,
  author = {Jacobson, Denise L and Crider, Krista S and DeMarrais, Patricia and Brummel, Sean and Zhang, Mindy and Pfeiffer, Christine M and Moore, Cynthia A and McCarthy, Katie and Johnston, Benjamin and Mohammed, Terence and Vhembo, Tichaona and Kabugho, Enid and Muzorah, Gerald Agaba and Cassim, Haseena and Fairlie, Lee and Machado, Elizabeth S and Ngocho, James S and Shapiro, Roger L and Serghides, Lena and Chakhtoura, Nahida and Chinula, Lameck and Lockman, Shahin},
  title = {Dolutegravir- Versus Efavirenz-Based Treatment in Pregnancy: Impact on Red Blood Cell Folate Concentrations in Pregnant Women and Their Infants},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  doi = {10.1093/infdis/jiae308}
}
Kostenlos starten →